mycophenolate mofetil / Generic mfg. - LARVOL DELTA

Convergence in age adjusted mortality rates and proportion of all deaths from COVID-19 among patients with hematologic malignancies, 2020-2024 (ASH 2025) - "One retrospective cohort study found no effect of immunosuppression with prednisone, tacrolimus, or mycophenolate mofetil on ventilation, in-hospital mortality or length of stay among hospitalized COVID-19 patients in one hospital system (Andersen et. There was a higher peak AAMR from COVID-19 as a proportion of all deaths in the general population during the heights of the COVID-19 pandemic (2020-2021) than among patients with HM as a share of all HM-associated deaths in the same period across all regions. The all-cause AAMR is higher at baseline among patients with HM, so the effect of COVID-19 may have been smaller in this population as a share of all deaths. Patients known to have HM may access care, take airborne precautions and vaccinate more regularly."

Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology • Solid Tumor

Enhanced outcomes for pediatric patients with de novo chronic myeloid leukemia in blast Phase through early allogeneic stem cell transplantation and tyrosine kinase inhibitor (ASH 2025) - "Specifically, dasatinib was administered to four patients, while olverembatinib for three patients...Prophylaxis for graft-versus-host disease (GVHD) routinely included cyclosporine A and mycophenolate mofetil, with or without methotrexate... Prompt HSCT for de novo CML-BP, combined with early TKI maintenance post-transplantation, appears to contribute to effective disease management. Additionally, unrelated cord blood donors seem to provide a viable source for transplantation. Furthermore, olverembatinib has demonstrated favorable safety and efficacy profiles both pre- and post-transplantation."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Pediatrics • Transplantation • ABL1

Outcomes of allogeneic hematopoietic stem cell transplantations (HSCT) for treatment of secondary primary malignancies arising post-autologous HSCT for multiple myeloma (ASH 2025) - "As conditioning regimens, 12 patients received Fludarabine/Busulfan, and 5 patients received Fludarabine/Melphalan...For GVHD prophylaxis, 6 patients received Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil (MMF); 9 patients received Thymoglobulin, Tacrolimus, and MMF; 1 patient received Thymoglobulin, Sirolimus, and MMF; 1 patient received Tacrolimus, Methotrexate, and Abatacept...Limitations of the outcome data include a relatively small population that underwent Allo-HCST, likely lower than the true number of patients with SPM following Auto-HSCT due to them either not returning to the center or opting against Allo-HSCT for treatment. This data adds to the collective understanding of the associated risks and benefits of Allo-HSCT for treatment of hematological SPM following Auto-HSCT for MM."

Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Multiple Myeloma • Myelodysplastic Syndrome • Oncology • Transplantation • TP53

CMV reactivation under foscarnet prophylaxis in cord blood transplantation: Increased NRM without impact on relapse or survival (ASH 2025) - "Prophylactic administration of letermovir was not performed. Tacrolimus and mycophenolate mofetil were used for GVHD prophylaxis... In CBT with early post-transplant prophylactic administration of FOS, CMV reactivation was associated with increased NRM, although no significant impact on relapse or OS was observed. CMV disease had a substantial negative impact on NRM and OS, underscoring the importance of timely intervention."

Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • CNS Disorders • Cytomegalovirus Infection • Epstein-Barr Virus Infections • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Nephrology • Pneumonia • Respiratory Diseases • Transplantation

Risk of relapse and mortality after non-myeloablative allogeneic stem cell transplant for Acute Myeloid Leukemia and myelodysplastic syndrome after fludarabine, cyclophosphamide, and 200 centigray total body irradiation with gvhd prophylaxis using post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil: Impact of maintenance chemotherapy (ASH 2025) - "Oral HMA agents were decitabine/cedazuridine (dec-c) 3d/28-day cycle, and oral azacitidine (Oral-Aza) for 14 days per 28-day cycle...A total of 32 (31%) patients received post-HSCT maintenance chemotherapy: infusional HMA (n=2), recombinant-Granulocyte Colony Stimulating Factor (rhGCSF)/decitabine (n=2), gilteritinib (n=7), dec-c (n=9), oral-aza (2), and venetoclax/Azacitidine (n=8)... NMA conditioning with Flu/Cy/2Gy TBI yields low NRM. Post-transplant maintenance therapy, particularly with HMAs and targeted agents, is associated with reduced relapse in intermediate-risk and adverse-risk TP53 wt AML and MDS. However, outcomes remain poor for patients with TP53 mu t AML and MDS, indicating an urgent need for alternative or intensified maintenance strategies in these high-risk groups."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myelomonocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation • FLT3 • TP53

Results of abatacept addition to post transplant cyclophosphamide-based GVHD prophylaxys in allogeneic hematopoyetic stem cell transplantation (ASH 2025) - "All patients received peripheral blood as graft source and all patients received GVHD prophylaxis with ABA in combination with PTCY, tacrolimus, and mycophenolate mofetil...Reduced-intensity conditioning regimens were used in the majority of patients in both cohorts (88.2% vs 93.4%, p=0.5), most commonly conditioning included busulfan-fludarabine or busulfan-cyclophosphamide-fludarabine. In the +56 cohort, 2 patients received clofarabine-melphalan, according to internal protocol, due to disease persistence prior to transplant.With a median follow-up of 15.7 months (range 7.4–31.1), estimated 1-year PFS and OS were 66% (IC95%= 0.5-0.7) and 72% (IC95%= 0.5-0.8)... Our experience suggests, compared with previous analysis ( P Fernandez-Caldas. EBMT 2024 ), that addition of ABA to PTCY-based prophylaxis, in peripheral blood stem cell setting, may reduce GVHD and allow early immunosuppression withdrawal without increasing GVHD rates, though sample size is limited."

Post-transplantation • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Myelodysplastic Syndrome • Transplantation • CTLA4

Connecting pharmacokinetic exposure to immune reconstitution: A pilot study in HLA-haploidentical hematopoietic cell transplant recipients (ASH 2025) - "Post-transplant cyclophosphamide (PTCy) and mycophenolate mofetil (MMF) are commonly used in combination with tacrolimus or sirolimus as standard-of-care prophylaxis of graft-versus-host disease (GVHD) for allogeneic hematopoietic cell transplant (alloHCT). The findings also suggest that renal dysfunction may increase exposure to Cy and MMF metabolites. Our data supported the need for further research in larger cohorts to investigate the relationship between pharmacokinetic biomarkers and clinical outcomes."

Clinical • PK/PD data • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Nephrology • Transplantation

Early detection of emerging safety signals in GVHD prophylaxis agents using a 12-year faers "slope-watch" approach (ASH 2025) - "In addition to tacrolimus and cyclosporine, contemporary prophylaxis regimens employ sirolimus and everolimus, mycophenolate mofetil, methotrexate, post-transplant cyclophosphamide (PTCy), JAK inhibitors (ruxolitinib, baricitinib, tofacitinib), co-stimulation blockade with abatacept, gut-homing integrin antagonism via vedolizumab, and the ROCK2 inhibitor belumosudil. Sequential IC-Δ offers a robust, forward-looking pharmacovigilance framework that identifies adverse event acceleration 12–24 months before regulatory action. By emphasizing directional change and incorporating a simple confidence approximation, this approach enhances early signal detection in large safety datasets. Integration with electronic health records, regulatory pipelines, and interactive dashboards could further streamline horizon scanning and improve patient safety in GVHD prophylaxis."

Clinical • Bone Marrow Transplantation • CNS Disorders • Cytomegalovirus Infection • Dyslipidemia • Graft versus Host Disease • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Metabolic Disorders • Pneumonia • Rare Diseases • Respiratory Diseases • Septic Shock

Real-world experience with ruxolitinib therapy for steroid-refractory acute graft-versus-host disease following umbilical cord blood transplantation (ASH 2025) - "GVHD prophylaxis consisted of tacrolimus (Tac) plus mycophenolate mofetil in 54 patients and Tac plus short-term methotrexate in 1. RUX therapy for SR-aGVHD following UCBT showed a meaningful response rate, with sustained benefit observed in responders. Although cytopenias and infections were frequently encountered, most patients were able to continue treatment. RUX may represent a viable treatment option for SR-aGVHD in the UCBT setting, with careful attention to adverse events."

Clinical • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cerebral Hemorrhage • CNS Disorders • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Influenza • Neutropenia • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia • Transplantation

Belumosudil is effective in patients with chronic graft-versus-host disease lasting more than two years: A retrospective single-center real-world study (ASH 2025) - "Resistance to the most recent prior therapy (including glucocorticoid, calcineurin inhibitors, mycophenolate mofetil, ruxolitinib, mesenchymal stem cells, etc.) was observed in 82.4% (n = 14). This real-world study demonstrates that belumosudil is efficacious, well-tolerable, and safe for recipients with cGVHD persisting for at least 2 years after diagnosis and following multiple lines of anti-cGVHD therapy. Most patients exhibit meaningful clinical improvement with belumosudil. No significant increase in the risk of disease recurrence or infection was observed."

Real-world • Real-world evidence • Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Gastrointestinal Disorder • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia

Line-of-therapy stratified efficacy of belumosudil in cgvhd : Real-world evidence (ASH 2025) - "For concomitant treatments, cyclosporine was more frequent in patients with 1 prior LOT (73.3% vs. 22.2%, P=0.033), whereas tacrolimus was more common in patients with ≥2 prior LOTs (13.3% vs. 66.7%, P=0.021). No statistically significant differences were observed for other concomitant treatments, including corticosteroid (73.3% vs. 33.3%, P=0.092), mycophenolate mofetil (80.0% vs. 66.7%, P=0.635) and JAK inhibitor (33.3% vs. 44.4%, P=0.678)... In this real-world analysis dedicated to pretreated cGVHD, belumosudil achieved 95.8% (23/24) ORR in overall cohort, with 100% ORR specifically in second-line therapy (15/15). The 88.9% ORR in patients with ≥2 prior LOTs (8/9), 41.7% steroid reduction, and no grade≥3 AEs support its prioritization for early second-line use."

Clinical • HEOR • Real-world • Real-world evidence • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

Sirolimus plus low-exposure calcineurin inhibitors as an alternative gvhd prophylaxis in CNI-intolerant recipients: A retrospective study (ASH 2025) - "The cohort (10 males, 6 females) had a median age of 22.5 years (range 5–60). The regimen was initiated a median of 27.5 days post-transplant (range –2 to 114) and continued for a median of 53 days. Five patients (31.2%) received sirolimus and low-dose CNI alone, 10 (62.5%) received additional mycophenolate mofetil (MMF), and 1 patient received MMF plus anti-CD25 antibody."

Retrospective data • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease

Exploring the efficacy and safety of low-dose ATG combined with fractionated low-dose ptcy in preventing gvhd after allogeneic hematopoietic stem cell transplantation (ASH 2025) - "Background In recent years, growing evidence has demonstrated the potential of anti-thymocyte globulin (ATG) combined with post-transplant cyclophosphamide (PTCY) as an effective strategy for graft-versus-host disease (GVHD) prophylaxis...The GVHD prophylaxis regimen consisted of low-dose ATG (2.5 mg/kg on days -2 and -1), fractionated low-dose PTCY (25 mg/kg on days +3 and +4), cyclosporine (2.5 mg/kg /day starting from day +5), and mycophenolate mofetil (0.5 g twice daily from day +5)...Conclusion GVHD prophylaxis with low-dose ATG combined with fractionated low-dose PTCY in allogeneic hematopoietic stem cell transplantation demonstrated excellent tolerability, with a remarkably low incidence of grade III-IV GVHD and absence of cardiac adverse events. However, due to the small sample size and short follow-up, further prospective, large-scale, multicenter randomized controlled trials are needed to validate the superiority of this regimen."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Mucositis • Stomatitis • Transplant Rejection • Transplantation

Single vs double cord blood transplantation: Improved engraftment with comparable efficacy (ASH 2025) - " Between April of 2006 and February of 2025, 315 patients with malignant disease underwent their first single (sCBT) or double CBT (dCBT) using a myeloablative conditioning regimen with FLU 75 mg/m2, TBI 13.2 Gy, CY 120 mg/kg (n=182) or FLU 150 mg/m2, TBI 4 Gy, CY 50 mg/kg, Thiotepa 10 mg/kg (n=47) or Treo 42 g/m2, FLU 150 mg/m2, TBI 2 Gy (n=86)...Graft-versus-host-disease (GVHD) prophylaxis included Cyclosporine and Mycophenolate Mofetil for all patients... In our study, sCBT was not inferior to dCBT with outstanding clinical outcomes. In fact, sCBT was associated with significantly faster neutrophil and platelet recovery. These findings encourage the use of sCBT in patients with an adequate cell dose, offering the potential to substantially reduce the cost of CBT without compromising efficacy."

Clinical • Acute Graft versus Host Disease • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Transplantation • CD34 • HLA-B • HLA-DRB1

A novel reduced-toxicity conditioning regimen with busulfan/fludarabine/cyclophosphamide/anti-thymocyte globulin for severe aplastic anemia (ASH 2025) - "The conditioning regimen comprised Bu (0.8 mg/kg every 6 hours, 1 day, weight-adjusted dose for pediatric patients), Flu (30 mg/m²/day, 4 days), Cy (500 mg/m²/day, 4 days), and ATG with Thymoglobulin 2 mg/kg/day, 4 days in 3 patients or ATG-Fresenius 5 mg/kg/day, 4 days in 7 patients. Graft-versus-host disease (GVHD) prophylaxis included cyclosporine and mycophenolate mofetil for all patients, supplemented with either: short-term methotrexate(MTX, +1d 15mg/m², +4d, +8d, +11d 10mg/m², n=2); only CD25 monoclonal antibody(Basiliximab, +3d 20mg, n=1); or both(MTX as above plus Basiliximab, +3d 20mg, n=2; or MTX as above plus Recombinant humanized anti-CD25 monoclonal antibody, +4d, +8d, 1mg/kg, n=5)...Majority of the patients are with good quality of life. Longer follow-up and larger series are needed to evaluate fertility and transplant outcomes with current protocol."

Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

Characterization and risk factors of transplantation-associated thrombotic microangiopathy (TA-TMA): Increased incidence associated to post-transplant cyclophosphamide (PTCy) prophylaxis. (ASH 2025) - "GVHD prophylaxis consisted of Tacrolimus-MTX in HLA-identical donor transplants with myeloablative conditioning regimen (27%), PTCy-based prophylaxis in haploidentical and other mismatched donor transplant with myeloablative conditionings (36%) and Tacrolimus-Sirolimus +/- mofetil mycophenolate in reduced-intensity conditioning regimen (36%). TA-TMA is associated with impaired OS, especially in those with organ involvement. PTCy is significant and independently linked to increased risk of TA-TMA, and co-occurrence of BK/JC cystitis or acute GVHD increased risk in these patients, suggesting that a closer monitorization should be implemented for them."

Clinical • Post-transplantation • Acute Graft versus Host Disease • Cardiovascular • Graft versus Host Disease • Hematological Disorders • Hypertension • Immunology • Renal Disease • Thrombosis • Transplantation

Haploidentical hematopoietic stem cell transplantation with bussulfan, fludarabine and cyclophosphamide and total body irradiation 200cgy conditioning with post-transplant cyclophosphamide and peripheral blood stem cells as an alternative regimen to reduce graft rejection in sickle cell disease (ASH 2025) - "Graft-versus-host disease (GvHD) prophylaxis included PTCy (50 mg/kg on days +3 and +4), mycophenolate mofetil, and sirolimus. Our data support the feasibility and safety of haploidentical HSCT using busulfan, fludarabine, and cyclophosphamide RIC combined with PTCy and PBSC in adult SCD patients. This approach yielded sustained full donor chimerism with low incidence of severe GvHD and graft failure, offering a practical alternative in resource-limited settings where thiotepa is not easily available. Considering the ongoing challenges in donor availability and conditioning toxicity, further studies with larger cohorts and longer follow-up are warranted to confirm the durability of engraftment, late effects, and overall survival benefits."

Post-transplantation • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Mucositis • Sickle Cell Disease • Transplant Rejection • Transplantation

Outcomes of standard versus reduced-doses post-transplant cyclophosphamide prophylaxis in matched sibling donor allogeneic hematopoietic cell transplant: A retrospective study at a single tertiary center in Saudi Arabia (ASH 2025) - "The patients were divided into two groups, those who received the standard dose (100 mg/kg) and those who received reduced-dose (70 mg/kg) PTCy-based prophylaxis which was divided in day +3 and day +4, both combined with Calcineurin inhibitors and Mycophenolate mofetil. In MSD allo-HSCT, the outcome of reduced- and standard-dose PTCy was comparable with possible clinical reduction hemorrhagic cystitis, fungal infections, bacterial infections and cardiac toxicity while maintaining a similar GVHD prevention, NRM and OS rates. A larger prospective study needed to demonstrate efficacy and safety."

Post-transplantation • Retrospective data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Transplantation

Transplant outcomes for children and adolescents with severe aplastic anemia comparing matched sibling donor and haploidentical transplant approaches. (ASH 2025) - "Introduction Recent studies comparing matched sibling donor (MSD) and haploidentical donor with post-transplant cyclophosphamide (haplo-PTCy) hematopoietic stem cell transplantation (HSCT) for children and adolescents with severe aplastic anemia (SAA) show promising results...GVHD prophylaxis included cyclosporine A (3–5 mg/kg) and mini-methotrexate...The conditioning regimen included ATG 4.5 mg/kg, fludarabine 150 mg/m², and total body irradiation 400 cGy. GVHD prophylaxis consisted of Cy 50 mg/kg on +3 and +4, followed by tacrolimus 0.06 mg/kg and mycophenolate mofetil 30 mg/kg starting on +5...Discussion and Conclusions Health-related quality of life outcomes is comparable between the two approaches, with no significative differences in overall survival between both transplant models. These results suggest that haplo-HSCT with PT-Cy is a viable alternative when an MSD is unavailable and may open the possibility of further research studies in which this transplant..."

Clinical • Acute Graft versus Host Disease • Anemia • Aplastic Anemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Hematological Disorders • Immunology • Infectious Disease • Respiratory Diseases • Transplantation

Outcomes of myeloablative vs reduced and non-myeloablative conditioning in MRD-negative AML and ALL with ptcy-based GVHD prophylaxis (ASH 2025) - "In the current post-transplant cyclophosphamide (PTCY) era, outcomes may differ given the widespread use of PTCY-based graft-versus-host disease (GVHD) prophylaxis...Reduced intensity conditioning included fludarabine 30mg/m 2 for 4 consecutive days plus 8 Gy TBI, or fludarabine plus either melphalan or busulfan, with 2 Gy TBI...All patients received PTCY in combination with a calcineurin inhibitor and mycophenolate mofetil as GVHD prophylaxis... In MRD-negative AML and ALL patients undergoing allo-HSCT with PTCY-based GVHD prophylaxis, NMA regimens appear to offer comparable survival and GVHD outcomes to MAC, with potentially lower toxicity. These findings suggest NMA conditioning may be a viable and safer alternative to MAC in select MRD-negative patients in the PTCY era."

Minimal residual disease • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia

Impact of antibiotic use in early fever after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide (ASH 2025) - "All patients received PTCY 50 mg/kg on days +3 and +4, followed by tacrolimus and mycophenolate mofetil as graft-versus-host disease (GVHD) prophylaxis...Eleven patients received tocilizumab for CRS grade ≥2. Levofloxacin prophylaxis was used in 72.8% of cases. Most (85/103, 82.5%) received empirical BSA, mainly piperacillin/tazobactam (67%)... The median patient age was 53 years, and 60.3% were male. The most frequent diagnosis was AML (38.8%). Most patients had intermediate disease risk (65.3%) and a high age-adjusted HCT-CI (76%)."

Post-transplantation • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease • Inflammation • Pneumonia • Transplantation • CRP

First report of successful, lifesaving and timely graft rescue using an off-the-shelf cryopreserved, cadaveric marrow in myeloablative transplant with an unexpected unavailability of a living matched unrelated donor. (ASH 2025) - " A 34-year-old male with AML (NPM1, FLT3 TKD, KRAS, PTPN11, WT1, and RAD21 mutations) in first complete remission (CR1) began myeloablative fludarabine/busulfan conditioning in preparation for a 10/10 HLA-matched unrelated donor peripheral blood stem cell transplant...GVHD prophylaxis consisted of tacrolimus, mycophenolate mofetil, and post-transplant cyclophosphamide (PTCy, 50 mg/kg/d on Days +3 and +4). Patient received filgrastim post-transplant... This case report illustrates the feasibility and life-saving potential of using cryopreserved bone marrow from deceased donors in urgent allo-HCT scenarios. Day 0 was delayed by only 48 hours and the product was identified within 24 hours of request. Timely access to an off-the-shelf marrow product prevented catastrophic graft failure or debilitating opportunistic infections."

Acute Myelogenous Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Transplantation • CD33 • CD34 • FLT3 • KRAS • NPM1 • PTPN11 • RAD21 • WT1

Daclizumab enhances aGVHD prophylaxis by modulating T-cell polarization while preserving the graft-versus-lymphoma effect (ASH 2025) - "Our prior clinical data showed that adding Daclizumab, an anti-CD25 monoclonal antibody, to standard prophylaxis (Mycophenolate mofetil/Tacrolimus/Methotrexate) significantly reduced grade 3–4 aGvHD incidence in thalassemia patients undergoing alternative donor HSCT. Daclizumab enhances aGvHD prophylaxis by modulating T-cell polarization—favoring Th2/Treg balance and reducing cytotoxicity—while preserving graft-versus-lymphoma effects. These findings support anti-CD25 antibodies as a promising strategy to optimize immune tolerance and anti-tumor efficacy post-transplantation."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Genetic Disorders • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • CD4 • CD69 • CD8 • GZMB • IFNG • IL17A • IL2 • IL4 • PRF1

Consolidation of dual MAPK inhibitor therapy by allograft in histiocytic sarcoma: A report of two cases (ASH 2025) - "Transplant proceeded using fludarabine 150mg/m 2 and melphalan 140mg/m 2 with post-grafting cyclophosphamide, mycophenolate mofetil and tacrolimus for graft-versus-host disease (GvHD) prophylaxis...He remains well on dabrafenib and trametinib in CMR at 16-months post-transplant...To consolidate this response, allograft from a haploidentical donor was performed using fludarabine 150mg/m 2 and melphalan 140mg/m 2 with post-grafting cyclophosphamide and ciclosporin for GvHD prophylaxis... These 2 cases suggest that allograft is feasible on dual MAPK inhibitor therapy and may have potential efficacy as consolidation for high-risk visceral HS. Withdrawal of inhibitors and longer follow up are required to determine the durability of remission with this approach."

Clinical • Cough • Gastroenterology • Gastrointestinal Disorder • Graft versus Host Disease • Immunology • Infectious Disease • Respiratory Diseases • Sarcoma • Solid Tumor • Tuberculosis • BCL6 • CCND1 • CD14 • CD163 • CD1a • KRAS • MAP2K1

A tale of two lymphomas: A rare case of transformative post-transplant lymphoproliferative disorder (ASH 2025) - "Our 61-year-old patient underwent a living-unrelated renal transplant in 2014 for focal segmental glomerulosclerosis and was maintained on mycophenolate mofetil (MMF) and cyclosporine (CsA)...MMF was discontinued, and he received four weekly doses of rituximab (375 mg/m²), achieving complete remission (CR) and was consolidated with four additional Rituximab doses by Jan 2024...After improvement of liver and kidney function, therapy was escalated to brentuximab vedotin (BV) with cyclophosphamide, doxorubicin, and prednisone (CHP), given his CD30 expression...After detailed goals-of-care discussions, he and the care team elected to proceed with additional therapy with EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), since he already received azacitidine, romidepsin, and BV-CHP...His care underscores the importance of multidisciplinary collaboration, patient-centered decision-making, and longitudinal follow-up. He has been referred to our..."

Clinical • IO biomarker • Post-transplantation • Bone Marrow Transplantation • Chronic Kidney Disease • Epstein-Barr Virus Infections • Febrile Neutropenia • Focal Segmental Glomerulosclerosis • Follicular Lymphoma • Glomerulonephritis • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Liver Failure • Lymphoma • Nephrology • Peripheral T-cell Lymphoma • Rare Diseases • T Cell Non-Hodgkin Lymphoma • Transplantation • BCL6 • CD21 • CD4 • CD5 • CD7 • ICOS • JAK1 • PD-1 • RHOA • TET2 • TNFRSF8